Rush | Strategic Alliance Partners

Latest from Rush

Dr. Rao on Abemaciclib Post-Palbociclib in Metastatic Breast Cancer

June 20, 2019

Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.

Dr. Jain on Results of Gender Disparities Study in Oncology

June 18, 2019

Shikha Jain, MD, hematologist/oncologist, Rush University Medical Center, discusses the disparities between male and female professionals at medical conferences, specifically the American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Fidler on Novel Chemotherapy Strategies in Nonsquamous NSCLC

June 18, 2019

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.